Gene Signatures of Tumor Inflammation and Epithelial-to-Mesenchymal Transition (EMT) Predict Responses to Immune Checkpoint Blockade in Lung Cancer with High Accuracy

Immune checkpoint blockade (ICB) using anti-PD1 [1,2] or anti-PD-L1 antibodies [3,4] has demonstrated enhanced response rates, progression free survival (PFS), and overall survival (OS) in non-small cell lung cancer (NSCLC) patients. However, only a subset of patients achieve durable clinical benefit. Since these therapies are associated with immune-related adverse events and have significant financial implications [5,6], a need exists for robust predictive biomarkers.

Source: Lung Cancer - October 17, 2019 Category: Cancer & Oncology Authors: Jeffrey C. Thompson, Wei-Ting Hwang, Christiana Davis, Charuhas Deshpande, Seth Jeffries, Yashoda Rajpurohit, Vinod Krishna, Denis Smirnov, Raluca Verona, Matthew V. Lorenzi, Corey J. Langer, Steven M. Albelda Source Type: research